bendamustine hydrochloride has been researched along with mk 2206 in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bowen, DA; Call, TG; Conte, M; Ding, W; Erlichman, C; Kay, NE; Kumar, S; Leis, JF; Lesnick, CE; Sassoon, TR; Secreto, C; Shanafelt, TD | 1 |
| Bowen, D; Boysen, J; Call, T; Conte, M; Ding, W; Erlichman, C; Habermann, TM; Hanson, C; Jelinek, D; Kay, NE; LaPlant, B; Larsen, JT; Leis, JF; Lesnick, C; Nikcevich, D; Pettinger, A; Reeder, C; Secreto, C; Shanafelt, TD; Tschumper, R | 1 |
1 trial(s) available for bendamustine hydrochloride and mk 2206
| Article | Year |
|---|---|
Akt inhibitor MK-2206 in combination with bendamustine and rituximab in relapsed or refractory chronic lymphocytic leukemia: Results from the N1087 alliance study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Heterocyclic Compounds, 3-Ring; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neoplasm Staging; Recurrence; Retreatment; Rituximab; Survival Analysis; Treatment Outcome | 2017 |
1 other study(ies) available for bendamustine hydrochloride and mk 2206
| Article | Year |
|---|---|
Akt inhibitor MK2206 selectively targets CLL B-cell receptor induced cytokines, mobilizes lymphocytes and synergizes with bendamustine to induce CLL apoptosis.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Bendamustine Hydrochloride; Cytokines; Drug Synergism; Heterocyclic Compounds, 3-Ring; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphocytes; Nitrogen Mustard Compounds; Proto-Oncogene Proteins c-akt | 2014 |